Trust Co lifted its stake in shares of Celgene Co. (NASDAQ:CELG) by 4.9% in the 3rd quarter, Holdings Channel reports. The firm owned 18,484 shares of the biopharmaceutical company’s stock after buying an additional 860 shares during the quarter. Trust Co’s holdings in Celgene were worth $2,695,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the company. Thompson Davis & CO. Inc. grew its holdings in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the period. Arcadia Investment Management Corp MI grew its holdings in Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the period. Robecosam AG acquired a new position in Celgene during the third quarter worth $114,000. Guidant Wealth Advisors acquired a new position in Celgene during the third quarter worth $119,000. Finally, Capital Bank & Trust Co grew its holdings in Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 517 shares during the period. Institutional investors and hedge funds own 78.93% of the company’s stock.

Shares of Celgene Co. (NASDAQ CELG) opened at $92.51 on Friday. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 3.52. Celgene Co. has a 12-month low of $88.32 and a 12-month high of $147.17. The stock has a market capitalization of $69,583.80, a price-to-earnings ratio of 25.84, a PEG ratio of 0.66 and a beta of 1.49.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. During the same period in the prior year, the business earned $1.61 earnings per share. The business’s revenue was up 16.9% on a year-over-year basis. sell-side analysts anticipate that Celgene Co. will post 7.68 EPS for the current fiscal year.

In related news, insider Mark J. Alles acquired 3,260 shares of Celgene stock in a transaction dated Thursday, February 8th. The shares were acquired at an average cost of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the transaction, the insider now directly owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.95% of the stock is owned by corporate insiders.

A number of research analysts recently weighed in on CELG shares. Royal Bank of Canada dropped their price objective on Celgene from $166.00 to $148.00 and set a “top pick” rating on the stock in a report on Friday, October 27th. Leerink Swann reaffirmed a “buy” rating and set a $156.00 price objective on shares of Celgene in a report on Friday, October 20th. Morgan Stanley dropped their price objective on Celgene from $120.00 to $115.00 and set an “underweight” rating on the stock in a report on Monday, October 23rd. Mizuho reissued a “buy” rating and issued a $128.00 target price on shares of Celgene in a report on Sunday, February 4th. Finally, SunTrust Banks lowered their target price on Celgene from $156.00 to $127.00 and set a “buy” rating on the stock in a report on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. Celgene presently has a consensus rating of “Buy” and a consensus price target of $130.35.

ILLEGAL ACTIVITY WARNING: This story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/02/11/trust-co-has-2-70-million-stake-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.